Ovagen
also known as ovarian peptide bioregulator
Short-peptide bioregulator from the Khavinson school, derived from ovarian tissue extracts. Proposed to support ovarian function through tissue-specific regulatory mechanisms. Evidence base limited to Russian-tradition research; PubMed-indexed studies sparse. Mechanism aligns with Khavinson's tissue-specific peptide theory — organ-derived peptides stimulate homeostasis in corresponding tissues via gene expression modulation.
At a glance
Oral / SQ · Protocol varies
Primary target — Ovarian tissue chromatin complexes.
Pathway — Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation.
Downstream effect — Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration.
Origin — Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids).
Feedback intact — Presumed physiological — Khavinson peptides described as regulatory, not replacement.
| Parameter | Value |
|---|---|
| Standard dose | 10–20 mg / day (oral) or 1–2 mg SQExtrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies. |
| Frequency | Once daily or cyclical (10–20 days per month)Cyclical protocols common in Khavinson bioregulator tradition. |
| Evidence basis | Theoretical / Russian-tradition |
| Duration | 4–12 weeks per cycleKhavinson protocols typically 1–3 months; repeat cycles as needed. |
| Route | Oral (capsule) or subcutaneousOral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- — Pregnancy
- — History of estrogen-sensitive tumors (monitor)
- — Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- — Endometriosis or fibroids (estrogen-responsive conditions)
- 01Oral route
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
- 02Subcutaneous route
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
- 03Cyclical protocol
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
- 04Storage
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
Sources
of 42 rendered claims carry a resolvable citation.
- [chalisova-2000]Chalisova 2000 — [Effect of cytomedins on development of organotypic culture of various tissues from the internal organs of rats].
journal, 2000 - [ilina-2024]Ilina 2024 — [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.].
journal, 2024 - [khavinson-2001]Khavinson 2001 — Tissue-specific effects of peptides.
journal, 2001 - [khavinson-2002]Khavinson 2002 — Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway.
journal, 2002